

- term use of ticagrelor in patients with prior myocardial infarction[J]. *N Engl J Med*, 2015, 373: 1274-1275.
- [6] WITTFELDT A, EMANUELSSON H, BRANDRUP-WOGENSEN G, VAN GIEZEN J J, JONASSON J, NYLANDER S, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans[J]. *J Am Coll Cardiol*, 2013, 61: 723-727.
- [7] GARCIA-DORADO D, OTAEGUI I, RODRIGUEZ PALOMARES J F, EVANGELISTA A, PINEDA V, RUIZ SALMERON R, et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI[J/OL]. *Eur Heart J*, 2013, 34(Suppl 1): 3736. doi: 10.1093/eurheartj/eh309.3736.
- [8] MINNER S A, SIMONE P, CHUNG B B, SHAH A P. Successful reversal of bradycardia and dyspnea with aminophylline after ticagrelor load[J]. *J Pharm Pract*, 2018, 31: 112-114.
- [9] RAMAKER'S B P, PICKKERS P, DEUSSEN A, RONGEN G A, VAN DEN BROEK P, VAN DER HOEVEN J G, et al. Measurement of the endogenous adenosine concentration in humans *in vivo*: methodological considerations[J]. *Curr Drug Metab*, 2008, 9: 679-685.
- [10] BONELLO L, LAINE M, KIPSON N, MANCINI J, HELAL O, FROMONOT J, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome[J]. *J Am Coll Cardiol*, 2014, 63: 872-877.
- [11] HUI Y, ZHAO S S, LOVE J A, ANSLEY D M, CHEN D D. Development and application of a LC-MS/MS method to quantify basal adenosine concentration in human plasma from patients undergoing on-pump CABG surgery[J]. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2012, 885/886: 30-36.
- [12] VIJAYAMAHANTESH, AMIT A, DIKHIT M R, MISHRA A, SINGH A K, DAS V N, et al. Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis[J]. *Cytokine*, 2017, 91: 170-179.
- [13] LI X, WANG Q, XUE Y, CHEN J, LV Q. Ticagrelor compared with clopidogrel increased adenosine and cyclic adenosine monophosphate plasma concentration in acute coronary syndrome patients[J]. *Basic Clin Pharmacol Toxicol*, 2017, 120: 610-614.
- [14] ORME R C, PARKER W A E, THOMAS M R, JUDGE H M, BASTER K, SUMAYA W, et al. Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI)[J/OL]. *Circulation*, 2018. pii: CIRCULATIONAHA.118.034790. doi: 10.1161/CIRCULATIONAHA.118.034790.
- [15] ORTEGA-PAZ L, BRUGALETTA S, ARIOTTI S, AKKERHUIS K M, KARAGIANNIS A, WINDECKER S, et al. Adenosine and ticagrelor plasma levels in patients with and without ticagrelor-related dyspnea[J]. *Circulation*, 2018, 138: 646-648.
- [16] ARIOTTI S, ORTEGA-PAZ L, VAN LEEUWEN M, BRUGALETTA S, LEONARDI S, AKKERHUIS K M, et al. Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers: a randomized crossover study[J]. *JACC Cardiovasc Interv*, 2018, 11: 1576-1586.
- [17] LIM S, CHOO E H, KIM C J, CHOI I J, LEE K Y, HWANG B H, et al. Ticagrelor does not improve endothelial dysfunction in stable survivors of acute coronary syndrome[J/OL]. *J Cardiovasc Pharmacol Ther*, 2019: 1074248419841640. doi: 10.1177/1074248419841640.
- [18] L(B, (·³, ¼ [5,, < S{, (·³, L ±. BK8£ nFû + h)Š"G % ' ā < æ6!8# Ô -*K < ö ¢ Ā=|; « **T +°,\$ Ÿ S[J]. • H g8', 2018,58:46-48.
- [19] LÖFGREN L, PEHRSSON S, HÄGGLUND G, TJELLSTRÖM H, NYLANDER S. Accurate measurement of endogenous adenosine in human blood[J/OL]. *PLoS One*, 2018, 13: e0205707. doi: 10.1371/journal.pone.0205707.
- [20] OHMAN J, KUDIRA R, ALBINSSON S, OLDE B, ERLINGE D. Ticagrelor induces adenosine triphosphate release from human red blood cells[J]. *Biochem Biophys Res Commun*, 2012, 418: 754-758.
- [21] ARMSTRONG D, SUMMERS C, EWART L, NYLANDER S, SIDAWAY J E, VAN GIEZEN J J. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1[J]. *J Cardiovasc Pharmacol Ther*, 2014, 19: 209-219.
- [22] LI P, GU Y, YANG Y, CHEN L, LIU J, GAO L, et al. /RZ GRVH WLF DJU HORU \LHOGV DQ D Q W to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial[J/OL]. *Sci Rep*, 2016, 6: 31838. doi: 10.1038/srep31838.
- [23] VAN GIEZEN J J, SIDAWAY J, GLAVES P, KIRK I, BJÖRKMAN J A. Ticagrelor inhibits adenosine uptake *in vitro* and enhances adenosine-mediated hyperemia responses in a canine model[J]. *J Cardiovasc Pharmacol Ther*, 2012, 17: 164-172.
- [24] VAN DEN BERG T N, EL MESSAOUDI S, RONGEN G A, VAN DEN BROEK P H, BILOS A, DONDEERS A R, et al. Ticagrelor does not inhibit adenosine transport at relevant concentrations: a randomized cross-over study in healthy subjects *in vivo*[J/OL]. *PLoS One*, 2015, 10: e0137560. doi: 10.1371/journal.pone.0137560.